文献速递造血干细胞移植与细胞治疗淋巴瘤

靶向同种异体反应性初始T细胞表面的VISTA表达促进免疫耐受

Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance.
PubMed 文献 · Blood · 2025-01-01

本文研究抗VISTA单克隆抗体通过清除同种异体反应性供者T细胞预防移植物抗宿主病(GVHD)的机制。单剂抗VISTA单抗在多种模型中预防急性GVHD致死,且依赖Fc受体介导的吞噬作用清除体内暴露的供者T细胞;在淋巴瘤攻击模型中移植物抗淋巴瘤效应完全或大部分保留,异种GVHD模型中降低供者T细胞扩增和受体致死率。

要点

  • 单剂抗VISTA单抗在多种模型中预防急性GVHD致死。
  • 抗VISTA单抗清除供者T细胞依赖Fc受体介导的吞噬作用。
  • 靶向供者CD4+ T细胞时移植物抗淋巴瘤效应完全保留。

核心结论

  • 这些数据支持一条新的临床转化路径:可在不抵消移植物抗淋巴瘤效应的情况下减轻急性GVHD致死性。

研究设计与样本

  • 研究采用多种模型:同种异体造血干细胞移植(allo-HSCT)模型、同基因受体对照、淋巴瘤攻击模型和异种GVHD模型。
  • 干预为单剂抗VISTA单克隆抗体(mAb),并测试与雷帕霉素或围移植期他克莫司GVHD预防的相容性。

主要发现

  • 供者初始T细胞表达中等水平VISTA,在allo-HSCT受者中随T细胞受体信号短暂升高,导致对anti-VISTA mAb介导清除的易感性增高,而同基因受者中的供者T细胞无此现象。
  • Anti-VISTA mAb清除供者T细胞与雷帕霉素相容,但与围移植期他克莫司GVHD预防不相容。
  • 仅靶向宿主细胞VISTA或供者CD8+ T细胞VISTA不能预防GVHD致死;anti-VISTA mAb介导的同种异体反应性供者T细胞删除依赖靶向第三种(非T)细胞类型。
  • 供者T细胞在体内同时暴露于anti-VISTA mAb(而非体外预孵育后过继转移)才被Fc受体(FcR)介导的吞噬作用清除。
  • 在淋巴瘤攻击模型中,抗人VISTA mAb仅靶向供者CD4+ T细胞时移植物抗淋巴瘤(GVL)效应完全保留;输注未分离供者T细胞时GVL效应延迟但大部分保留。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be limited by graft-versus-host disease (GVHD). T-cell activation is a key factor in GVHD progression. Costimulatory signals can be counterbalanced by coinhibitory signals such as the checkpoint molecule VISTA (V-domain immunoglobulin-containing suppressor of T-cell activation)/programmed death-1 homolog that restrains activation and maintains donor T-cell quiescence. A single dose of anti-VISTA monoclonal antibody (mAb) prevents acute GVHD lethality in multiple models. Naïve donor T cells express moderate VISTA levels, which transiently increase in allo-HSCT recipients in association with T-cell receptor signaling, leading to heightened susceptibility to anti-VISTA mAb-mediated depletion, in contrast to donor T cells transferred to syngeneic recipients. Anti-VISTA mAb donor T-cell depletion was compatible with rapamycin but incompatible with peritransplant tacrolimus GVHD prophylaxis. Targeting VISTA exclusively on host cells or donor CD8+ T cells was not protective against GVHD lethality. Instead, anti-VISTA mAb-mediated deletion of alloreactive donor T cells depended on targeting a third (non-T) cell type. Further mechanistic studies indicated that donor T cells concurrently exposed to anti-VISTA mAb in vivo but not preincubated in vitro before adoptive T-cell transfer were eliminated via Fc receptor (FcR)-mediated phagocytosis. In a lymphoma challenge model, a graft-versus-lymphoma (GVL) effect was fully retained when anti-human VISTA mAb exclusively targeted donor CD4+ T cells, and was delayed but mostly retained when unseparated donor T cells were infused. In a xenogeneic GVHD model, anti-human VISTA mAb reduced donor T-cell expansion, VISTA T-cell expression levels, and recipient lethality. Together, these data support a novel clinical translational pathway in which acute GVHD lethality can be mitigated without negating the GVL effect.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Koehn BH, Nowak EC, Skopelja-Gardner S, et al. Targeting cell-surface VISTA expression on allospecific naïve T cells promotes tolerance. Blood. 2025. PMID: 39919264. doi:10.1182/blood.2024025884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。